focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.15
Bid: 8.10
Ask: 8.20
Change: 0.00 (0.00%)
Spread: 0.10 (1.235%)
Open: 8.20
High: 8.20
Low: 8.15
Prev. Close: 8.15
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Solar Foods receives Euro34 million in grant

23 Dec 2022 07:00

RNS Number : 6926K
Agronomics Limited
23 December 2022
 

23rd December 2022

 

Agronomics Limited

 

("Agronomics" or the "Company")

 

Portfolio Company Solar Foods Receives a €34 million Grant to

Support Funding for its First Fermentation Commercial Facility

 

Agronomics, the leading listing company in cellular agriculture, is delighted to share that its Finnish portfolio company Solar Foods Oy, "Solar Foods", focused on commercialising its Solein protein made from air, has received a €34 million grant to support the build of their first fermentation facility and start preparations for their full scale facility. Agronomics has invested a total of 6 million to date and owns approximately 5.80% of Solar Foods, subject to conversion of the outstanding CLN.

 

The full announcement is set out below without any material changes.

 

 

Solar Foods receives a €34 million grant to ramp-up Factory 01 and start preparations for Factory 02

 

Business Finland has approved a €34 million grant funding to Solar Foods. To date, this is the single largest public grant funding for cellular agriculture in the world. The grant is the first batch of funding for Solar Foods due the recent IPCEI notification.

In September 2022, Solar Foods was selected to be a part of the European Commission's strategic hydrogen economy core. Solar Foods' €600 million investment programme, which also includes the future Factory 02, was notified as a hydrogen IPCEI (Important Project of Common European Interest) project with a maximum state aid of €110 million.

In alignment with the R&D phase plan of the IPCEI notification, Solar Foods will use the grant to ramp up its hydrogen fermentation facility, Factory 01, and enter the engineering phase with the following Factory 02.

The 'hydrogen IPCEI' initiative is about research, innovation, and first industrial deployment (FID) of relevant infrastructure in the European hydrogen value chain. The grant decision announced today supports the first phase of the IPCEI project roadmap where the engineering, construction and ramp-up of Solar Foods Factory 01 is a central piece.

"With Christmas on the doorstep, we will see social media full of unboxing videos. For us, this grant is not a Christmas present but the result of one and a half years of negotiation and the hard work done by the people behind the Finnish innovation system", Pasi Vainikka, CEO and co-founder of Solar Foods says.

"The grant demonstrates how Finland's innovation system is ready to think outside the box and wants to support the commercialisation of scientific discoveries emerging from the intersections of scientific disciplines. We do not really fit into any single traditional research and innovation category: we do clean-tech, food-tech, hydrogen technology and on a systemic level support the restoration of natural ecosystems."

Solar Foods' Factory 01 has reached its full roof height at Vantaa, Finland, and process installations are set to begin on Q1/2023. Factory 01 is aimed to be fully operational in Q1/2024. The data and operational experiences from the factory are applied in finalising the engineering for Factory 02.

What is Solein?

●  Solein is a microbial protein-rich powder that contains all the essential amino acids. It can be used to replace existing proteins in a variety of foods, for example in alternative dairy and meat, different snacks and beverages, noodles and pasta, or breads and spreads. It is the first ever novel food disconnected from the limits of traditional agriculture. This type of production method has the potential to transform the sustainability, availability and transparency of what we eat and where food can be produced.

●  Solein is produced using a bioprocess where microbes are fed with gases (carbon dioxide, hydrogen, and oxygen) and small amounts of nutrients. The bioprocess resembles winemaking, with carbon dioxide and hydrogen replacing sugar as the source of carbon and energy, respectively.

●  Solein is 65-70% protein, 5-8% fat, 10-15% dietary fibres and 3-5% mineral nutrients. The macronutrient composition of Solein cells is very similar to that of dried soy or algae. Solein provides iron and B vitamins and is exceptionally functional. Solein can be used with a wide variety of other ingredients: it vanishes into foods and doesn't change the taste of familiar, everyday food products.

The production of Solein is not reliant on agriculture, weather, or climate: it can be produced in harsh conditions such as deserts, Arctic areas, even space. The process does not require animals or photosynthetic plants, making Solein the world's most sustainable protein.

Solein will become available for commercial use for the first time. It is aimed at food brands looking for nutritious, functional, and sustainable protein ingredients of consistent quality that can be reliably delivered for their products. Singapore is the first market to grant Solein a regulatory approval, but Solar Foods is also seeking authorisations in other markets across the world.

●  Factory 01 is Solar Foods' first commercial production facility, which will begin to produce Solein in 2024. Construction of the facility started in Vantaa, Finland during Q4 2021. Factory 01 will scale Solein production to a level where it can be brought to market for the first time. Solar Foods has plans to expand its network of production facilities in the coming years.

 Learn more about Solein at www.solein.com

For more information and requests for interviews:

Solar Foods Ltd.

Pasi Vainikka

DSc (Tech), CEO

pasi@solarfoods.com

+358 10 579 3286

About Solar Foods Ltd.

Solar Foods produces protein using carbon dioxide and electricity. Solein production, independent of weather and climate conditions, liberates global protein production from the constraints of traditional agriculture. Solar Foods was founded in Espoo, Finland, in 2017 by Dr Pasi Vainikka, Dr Juha-Pekka Pitkänen, Sami Holmström, Jari Tuovinen, Professor Jero Ahola, and Janne Mäkelä as a spinoff from VTT Technical Research Centre of Finland and LUT University. www.solarfoods.com

 

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃'

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 4 billion has been invested worldwide since the industry's inception in 2016.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKBBNKBDBABB
Date   Source Headline
4th Dec 20197:00 amRNSUpdate on Placing and Final Results
11th Nov 20197:00 amRNSProposed Fundraise
29th Oct 20197:00 amRNSInvestment in Shiok Meats Pte. Ltd.
22nd Oct 20192:00 pmRNSCompany Newsletter
17th Oct 20197:00 amRNSInvestment in VitroLabs Inc
15th Oct 20197:00 amRNSInvestment in Rebellyous Foods
8th Oct 20197:00 amRNSNet Asset Value(s)
23rd Sep 20191:00 pmRNSAIM Rule 17 Notification
12th Sep 20197:00 amRNSInvestee Company Update
9th Sep 201911:55 amRNSHolding(s) in Company
5th Sep 20197:00 amRNSSeed Investment in Bond Pets LLC
29th Aug 20197:00 amRNSAgronomics Participates in BlueNalu Fund Raise
28th Aug 20199:42 amRNSNew website launched
27th Aug 20191:21 pmRNSInvestee company Update: Blue Nalu, Inc
12th Aug 201912:51 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSNet Asset Value(s)
29th Jul 20197:00 amRNSInvestment in Simply Foods, Inc. (New Age Meats)
5th Jul 20194:40 pmRNSSecond Price Monitoring Extn
5th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 201912:58 pmRNSResult of Meeting
17th Jun 20192:05 pmRNSSecond Price Monitoring Extn
17th Jun 20192:00 pmRNSPrice Monitoring Extension
17th Jun 201911:00 amRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSEquity Fundraise Closes at £4.5 million
10th Jun 20197:00 amRNSProposed Equity Fundraise
31st May 20199:30 amRNSBoard Appointments
16th Apr 20191:01 pmRNSResult of Meeting
10th Apr 20197:00 amRNSNet Asset Value
29th Mar 20197:00 amRNSCircular and Notice of General Meeting
29th Mar 20197:00 amRNSHalf-year Report
7th Feb 20197:00 amRNSNet Asset Value(s)
28th Dec 20182:20 pmRNSFinal Results
24th Oct 20187:00 amRNSNet Asset Value(s)
16th Aug 20187:00 amRNSInvestment in Blue Nalu, Inc.
18th Jul 20187:00 amRNSNet Asset Value(s)
28th Jun 20187:00 amRNSInvestee Company Update: Summit Therapeutics plc
23rd Apr 20187:00 amRNSNet Asset Value(s)
27th Mar 20189:30 amRNSHalf-year Report
9th Feb 201812:31 pmRNSResult of AGM
8th Feb 20187:00 amRNSChange of Adviser
22nd Jan 20187:00 amRNSNet Asset Value(s)
28th Dec 20174:49 pmRNSFinal Results
19th Oct 20177:00 amRNSNet Asset Value(s)
20th Jul 201711:00 amRNSNAV & Investment in AgeX Therapeutics Inc.
25th Apr 20177:00 amRNSRedemption of Interest in Magna Biopharma Fund
12th Apr 20177:00 amRNSNet Asset Value(s)
29th Mar 20177:00 amRNSHalf-year Report
10th Feb 20175:29 pmRNSResult of AGM
12th Jan 20177:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.